{"Symbol": "ALGS", "AssetType": "Common Stock", "Name": "Aligos Therapeutics\u00a0Inc", "Description": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.", "CIK": "1799448", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080", "OfficialSite": "https://www.aligos.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "42521300", "EBITDA": "-85820000", "PERatio": "None", "PEGRatio": "None", "BookValue": "11.67", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-13.54", "RevenuePerShareTTM": "0.299", "ProfitMargin": "0", "OperatingMarginTTM": "-38.27", "ReturnOnAssetsTTM": "-0.547", "ReturnOnEquityTTM": "-1.418", "RevenueTTM": "2646000", "GrossProfitTTM": "-65800000", "DilutedEPSTTM": "-13.54", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.416", "AnalystTargetPrice": "68.2", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "3", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "16.07", "PriceToBookRatio": "0.592", "EVToRevenue": "0.383", "EVToEBITDA": "0.575", "Beta": "2.66", "52WeekHigh": "24.32", "52WeekLow": "3.76", "50DayMovingAverage": "9.14", "200DayMovingAverage": "8.49", "SharesOutstanding": "5353600", "SharesFloat": "3138400", "PercentInsiders": "10.366", "PercentInstitutions": "60.744", "DividendDate": "None", "ExDividendDate": "None"}